Financial Position - As of September 30, 2025, the company had cash on hand of $8.4 million, with outstanding capital commitments primarily in the Bakken region[40]. - Cash and cash equivalents were $41.6 million as of September 30, 2025, compared to $42.5 million at December 31, 2024[69]. - The Partnership expects sufficient liquidity to fund distributions despite uncertainties from global military conflicts and inflation[67]. - The Partnership's capital resources primarily come from cash flows from Royalty Properties and NPI, with distributions determined after expenses[64]. - The Partnership is prohibited from incurring indebtedness exceeding $50,000, excluding trade payables[66]. Revenue and Sales Performance - For the three months ended September 30, 2025, natural gas sales volumes from Royalty Properties increased by 2% to 1,607 mmcf compared to 1,569 mmcf in the same period of 2024, while oil sales volumes decreased by 23% to 493 mbbls[52]. - The average sales price for Royalty Properties natural gas increased by 145% to $2.35/mcf in Q3 2025, compared to $0.96/mcf in Q3 2024[52]. - Cash receipts from Royalty Properties in Q3 2025 totaled $33.0 million, with 70% from oil sales and 30% from prior sales periods[62]. - Average realized prices for oil and natural gas sales from Royalty Properties were $57.83/bbl and $2.05/mcf, respectively[62]. - Cash receipts from the Partnership's NPI in Q3 2025 amounted to $5.1 million, with 47% from recent sales and 53% from prior periods[63]. - Average realized prices for oil and natural gas sales from NPI properties were $64.45/bbl and $2.82/mcf, respectively[63]. Operating Costs and Expenses - Operating costs, including production taxes, increased by 5% from Q3 2024 to Q3 2025, primarily due to higher natural gas production taxes and post-production costs[56]. - Depreciation, depletion, and amortization increased by 69% from Q3 2024 to Q3 2025, reflecting significant changes in estimates of oil and natural gas reserves[57]. - General and administrative expenses rose by 16% from the first nine months of 2024 to the same period of 2025, driven by increased legal fees and higher compensation expenses[58]. - Net cash provided by operating activities decreased by 3% from the first nine months of 2024 to the same period of 2025, primarily due to lower NPI payment receipts[59]. Acquisitions and Commitments - The company acquired mineral interests totaling approximately 3,050 net royalty acres in Adams County, Colorado, valued at $23.0 million on August 29, 2025[46]. - Lease bonus revenue for the first nine months of 2025 included $3.6 million from a lease extension in Reagan County, Texas, executed at $15,000 per acre with a 25% royalty[55]. Market and Risk Factors - The company continues to monitor factors impacting commodity supply and demand, including geopolitical tensions and tariff impacts, which may affect future profitability[42]. - There have been no significant changes in exposure to market risk during the three months ended September 30, 2025[72]. Lease Obligations - The total lease obligation for the office space is $842,000, with future lease payments totaling $1.276 million[65].

Financial Performance - Total revenue for Q3 2025 was $27.6 million, up from $16.0 million in Q3 2024, primarily due to a $25.0 million milestone from Johnson & Johnson and $1.0 million in royalty revenues[13] - Net loss for Q3 2025 was $19.6 million, an improvement from a net loss of $29.9 million in Q3 2024, attributed to increased revenue[13] - Revenue from research and development collaborations for Q3 2025 was $27,614,000, a 72.9% increase from $16,000,000 in Q3 2024[19] - Basic net loss per common share for Q3 2025 was $(0.26), an improvement from $(0.39) in Q3 2024[19] - Loss from operations for the nine months ended September 30, 2025, was $48,397,000, significantly improved from $114,893,000 for the same period in 2024[19] Expenses - Research and Development (R&D) expenses were $35.6 million in Q3 2025, slightly down from $36.4 million in Q3 2024, reflecting a decrease in expenses for several product candidates[13] - Total operating expenses for Q3 2025 were $49,724,000, slightly down from $50,205,000 in Q3 2024[19] Cash and Assets - Cash resources as of September 30, 2025, were $299.4 million, projected to fund operations into the second half of 2027[14] - Cash, cash equivalents, and short-term marketable securities increased to $251,933,000 as of September 30, 2025, up from $225,776,000 at the end of 2024[20] - Total assets decreased to $397,269,000 as of September 30, 2025, down from $463,091,000 at the end of 2024[20] - Stockholders' equity as of September 30, 2025, was $320,064,000, a decrease from $338,768,000 at the end of 2024[20] - Total liabilities decreased to $77,205,000 as of September 30, 2025, down from $124,323,000 at the end of 2024[20] Clinical Development - Initial Phase 1 clinical data for ZW191 showed an overall objective response rate of 53% and 64% for gynecological cancers[10] - The first patient was dosed in the Phase 1 trial of ZW251 for hepatocellular carcinoma, indicating progress in clinical development[7] - Zymeworks achieved a $25.0 million development milestone from Johnson & Johnson in Q3 2025 related to the clinical progress of pasritamig[11] Shareholder Actions - Share repurchases totaled $22.7 million as of November 4, 2025, under a $30.0 million program, enhancing shareholder value[13] - The company appointed Dr. Adam Schayowitz as Acting Chief Development Officer to support its strategic vision and advance its product portfolio[11] Accounts Receivable - Accounts receivable decreased to $29,352,000 as of September 30, 2025, from $55,815,000 at the end of 2024[20]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from_____________________ to ___________________ Commission file number 0-13222 CITIZENS FINANCIAL SERVICES, INC. (Exact name of registrant as specified in its charter) ( ...

Financial Performance - Total net sales for Q3 2025 were $2.73 billion[11] - GAAP net loss for the quarter was $139 million[11] - Adjusted Net Income attributable to common stockholders was $121 million[11] - Adjusted EBITDA for Q3 2025 was $302 million[11] - Adjusted Diluted EPS for the quarter was $0.14[11] Cash and Debt Position - Cash and cash equivalents stood at $2.3 billion[11] - Total debt, excluding finance lease obligations, was $3.1 billion[11] Future Growth Strategy - The company aims for $50 billion in annual revenues within the next decade through acquisitions and organic growth[7] Regulatory and Reporting - The refinancing of Term Loan B is subject to market conditions and no assurances are made regarding its completion[2] - The quarterly report on Form 10-Q for Q3 2025 is expected to be filed on November 6, 2025[3]

loanDepot announces third quarter 2025 financial results Reshaped leadership team focused on capitalizing on loanDepot's unique set of assets to drive operational excellence and profitable market share growth. Positive Q3 momentum from higher revenue and positive operating leverage. Highlights: IRVINE, Calif., November 06, 2025 - loanDepot, Inc. (NYSE: LDI), (together with its subsidiaries, "loanDepot" or the "Company"), today announced results for the third quarter ended September 30, 2025. "A key part of ...

Financial Performance - Total net sales for Q3 2025 were $2.73 billion[11] - GAAP net loss for Q3 2025 was $139 million[11] - Adjusted Net Income attributable to common stockholders was $121 million[11] - Adjusted EBITDA for Q3 2025 was $302 million[11] - Adjusted Diluted EPS for Q3 2025 was $0.14[11] Cash and Debt Position - Cash and cash equivalents stood at $2.3 billion[11] - Total debt, excluding finance lease obligations, was $3.1 billion[11] - Total net debt is expected to remain consistent following the refinancing[5] Future Outlook - The company aims for $50 billion in annual revenues within the next decade through acquisitions and organic growth[7] - The quarterly report on Form 10-Q for Q3 2025 is expected to be filed on November 6, 2025[3]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☑ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarterly Period Ended September 30, 2025 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File No. 0-15950 FIRST BUSEY CORPORATION (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (I.R.S. Em ...

Financial Performance - Revenue for Q3 2025 was $215.1 million, representing a 12% increase year-over-year[5] - GAAP net income for Q3 2025 was $26.3 million, or $0.34 per diluted share, compared to $0.1 million in Q3 2024[5] - Non-GAAP operating income increased by 81% year-over-year to $41.3 million in Q3 2025[5] - Loans revenue surged by 66% year-over-year to $39.6 million, driven by growth in personal and mortgage loans[6] - Emerging verticals revenue grew by 83% year-over-year to $46.9 million, primarily due to banking product growth[6] - Insurance revenue increased by 3% year-over-year to $70.9 million[6] - Credit cards revenue decreased by 25% year-over-year to $34.1 million, impacted by headwinds in organic search traffic[6] - Net income for the nine months ended September 30, 2025, was $34.7 million, compared to a net loss of $8.2 million in the same period of 2024[17] - Non-GAAP operating income for the nine months ended September 30, 2025, was $71.3 million, representing a 132% increase compared to $30.8 million in 2024[26] - Adjusted EBITDA for the nine months ended September 30, 2025, was $108.3 million, a 41% increase from $77.1 million in 2024[26] - The company reported a significant increase in income from operations, reaching $45.8 million for the nine months ended September 30, 2025, compared to $0.7 million in 2024[26] Cash and Assets - Cash and cash equivalents rose by 68% year-over-year to $120.6 million[7] - Total assets increased to $492.8 million as of September 30, 2025, up from $437.6 million at the end of 2024[16] - Cash and cash equivalents at the end of the period increased to $120.6 million from $71.7 million in the previous year[17] Forecasts and Projections - The forecasted 2025 annual GAAP operating income is projected to be in the range of $59-$63 million, with non-GAAP operating income expected to be between $91-$95 million[29] - The forecasted adjusted EBITDA for 2025 is expected to be in the range of $141-$145 million[29] - Revenue is expected to be in the range of $207-$215 million, representing a 15% year-over-year increase at the midpoint[32] - GAAP operating income is projected to be between $13 million and $17 million for Q4 2025[31] - Non-GAAP operating income is anticipated to be in the range of $20 million to $24 million for Q4 2025[31] - Adjusted EBITDA is expected to be between $33 million and $37 million[32] - Full year 2025 GAAP operating income is forecasted to be between $59 million and $63 million[31] - Full year 2025 non-GAAP operating income is projected to be in the range of $91 million to $95 million[31] Marketing and Spending - The company underspent on brand marketing by $8 million in Q3 2025, with plans to return to typical spending levels in Q4[6] - Stock-based compensation decreased to $21.6 million for the nine months ended September 30, 2025, down 22% from $27.7 million in 2024[26] Risks and Strategic Focus - The company faces significant risks and uncertainties that may affect actual results compared to forward-looking statements[34] - The company aims to grow traffic, engagement, and monetization on its platform while expanding within existing and new verticals[37] - The company is focused on developing scalable technology and enhancing user engagement through personalized guidance[37]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 (212) 891-2880 (Registrant's telephone number, including area code) Portman Ridge Finance Corporation TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 814-00735 BCP Investment Corporation (Exact nam ...

Financial Performance - The company had approximately $60.6 million in cash, cash equivalents, and short-term investments as of September 30, 2025, with a projected runway into Q1 2027[4][5]. - Total operating expenses for Q3 2025 were approximately $12.1 million, a decrease of $0.7 million from $12.8 million in Q3 2024, primarily due to reduced clinical trial expenses[6]. - Net cash used in operating activities for Q3 2025 was approximately $10.8 million, an increase of $0.3 million from $10.5 million in the same period in 2024[4]. - The net loss attributable to common stockholders for Q3 2025 was $11.3 million, compared to a net loss of $11.9 million in Q3 2024[12]. - The company reported royalty revenues of $120,000 for Q3 2025, down from $165,000 in Q3 2024[12]. - Total assets as of September 30, 2025, were $63.8 million, down from $97.2 million as of December 31, 2024[14]. Clinical Trial Updates - Cardiff Oncology reported a 19% improvement in confirmed objective response rate (ORR) for the 30mg onvansertib cohort compared to the control arm in the ongoing Phase 2 CRDF-004 trial for first-line RAS-mutated metastatic colorectal cancer (mCRC) as of July 8, 2025[2]. - The median progression-free survival (PFS) has not yet been reached, but early PFS data show a trend favoring the 30mg onvansertib arm versus control[3]. - The company expects to provide an update from the ongoing Phase 2 CRDF-004 trial in Q1 2026[3]. Market Opportunity - Onvansertib is positioned to address a significant medical need, with approximately 150,000 new colorectal cancer patients diagnosed annually in the U.S.[2].